Trial · NCT04340076
Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis
NCT04340076, Phase 4, Completed, Radboud University Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis. Trials, record NCT04340076. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04340076
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis
- NCT number
- NCT04340076
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 244 participants, actual
- Lead sponsor
- Radboud University Medical Center
- Conditions
- Psoriasis, Psoriasis Vulgaris
- Interventions
- Secukinumab, Ixekizumab, Brodalumab, Guselkumab, Risankizumab, Tildrakizumab, Bimekizumab
- First posted
- 2020-04-09
- Last updated
- 2026-03-17
- Other registries' IDs
- eudract:2019-004230-42
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Non-inferiority of the incidence proportion of persistent flares (Psoriasis Area and Severity Index (PASI) >5 for ≥ 3 months). | 18 months | |
| Secondary | Whether participants will have successful DR after 12 and 18 months, defined as using a lower dose than the normal dose and PASI ≤ 5. | 18 months | Definition of successful dose reduction: lower dose than the normal dose and PASI≤ 5. |
| Secondary | Psoriasis disease activity, measured with the Psoriasis Area and Severity Index (PASI) at each 3-monthly study visit. | 18 months | |
| Secondary | Dermatology-related quality of life as measured with the Dermatology Life Quality Index (DLQI) at each 3-montly study visit. | 18 months | |
| Secondary | Whether participants will have short disease flares throughout the study period (18 months), defined as a PASI > 5 at one time point. | 18 months | |
| Secondary | Whether other anti-psoriatic medication will be initiated in participants during the study period (18 months). | 18 months | |
| Secondary | Whether participants will have serious adverse events (SAE) and adverse events of special interest (AEoSI) during the study period. | 18 months | AEoSI include, but are not limited to, infections, malignancies, and joint complaints or new-onset psoriatic arthritis. |
| Secondary | Drug trough levels of each included drug, measured in blood serum samples which will be collected from participants at each 3-montly time point. | 18 months | |
| Secondary | Anti-drug antibody levels of each included drug, measured in blood serum samples which will be collected from participants at each 3-montly time point. | 18 months | |
| Secondary | Utilities, derived from EuroQoL 5 Dimensions (EQ-5D-5L) questionnaires, which will be measured at each 3-montly time point. | 18 months | Utility scores will be used to calculate quality adjusted life years (QALYs) which are used to determine cost-effectiveness of DR. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04340076
GET https://conductscience.org/api/trials/v1/NCT04340076/registered